10 completed, 9 terminated, 4 recruiting, 4 withdrawn. 32 Phase 2, 6 Phase 1, 2 Phase 3.
Follow capmatinib: new trials by email Literature Review of capmatinib trials Research Report on capmatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations Dabrafenib + Trametinib, Capmatinib - NSCLC, BRAF V600 Mutation | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2024-02-01 | 2023-10-10 |
| Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations Capmatinib - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Timothy Burns, MD, PHD | 2023-10-03 | 2024-06-17 | |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) Biospecimen Collection, Capmatinib, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 66 | 2023-05-05 | 2026-06-03 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Capmatinib, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 57 | 2022-12-13 | 2026-11-03 |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 10 | 2022-08-18 | 2025-06-11 |
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC capmatinib - Non-small Cell Lung Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 4 | 2022-08-10 | 2025-10-16 |
| Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma Capmatinib, Spartalizumab - Oesophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | Suspended | Assistance Publique - Hôpitaux de Paris | 90 | 2022-03-22 | 2023-02-03 |
| Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Capmatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2021-05-17 | 2026-03-31 |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases Capmatinib - Non-small Cell Lung Carcinoma (NSCLC) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2020-11-11 | 2020-12-03 | |
| Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations Spartalizumab, Capmatinib, spartalizumab placebo - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Novartis Pharmaceuticals | 31 | 2020-08-19 | 2024-10-09 |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% Capmatinib, Pembrolizumab - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | Novartis Pharmaceuticals | 76 | 2020-01-22 | 2024-10-09 |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Capmatinib, Spartalizumab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Novartis Pharmaceuticals | 18 | 2018-12-26 | 2022-01-24 |
| Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation Capmatinib - Cancer, Lung Cancer Metastatic | Phase 2 | Unknown | Asan Medical Center | 27 | 2018-10-30 | 2018-10-03 |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma PDR001, LAG525, INC280 - Melanoma | Phase 2 | Completed | Novartis Pharmaceuticals | 196 | 2018-09-10 | 2024-06-18 |
| Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) INC280 - Carcinoma, Non-Small-Cell Lung Cancer | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-07-31 | 2018-07-26 | |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone Capmatinib, Nazartinib, Gefitinib - Advanced Solid Tumors Which Are cMET-dependent | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 29 | 2017-07-04 | 2026-09-09 |
| Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma INC280, Placebo - Advanced Hepatocellular Carcinoma | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-12-01 | 2016-09-01 | |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
Showing 20 of 32. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (15) · Adenocarcinoma of Lung (5) · Lung Neoplasms (5) · Neoplasms (4) · Melanoma (3) · Hematologic Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Adenocarcinoma Of Esophagus (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Glioblastoma (1) · Glioma (1)
Novartis Pharmaceuticals (18) · Cancer Research UK (2) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Janssen Research & Development, LLC (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · SWOG Cancer Research Network (1) · Sun Yat-sen University (1) · Timothy Burns, MD, PHD (1) · University of California, San Francisco (1)
United States (17) · France (14) · Germany (14) · Spain (14) · Italy (12) · Canada (8) · China (8) · South Korea (8) · Australia (7) · Netherlands (7) · United Kingdom (7) · Belgium (6) · Singapore (6) · Japan (5) · Switzerland (5)
Matthew Krebs, Dr (2) · Adil Daud (1) · Birgit Geoerger, MD (1) · Rachel Layman (1) · Ramaprasad Srinivasan, M.D. (1) · Rebecca S. Heist, MD (1) · Sarah B Goldberg (1) · Timothy F Burns, MD, PhD (1)
PMID 26825170, PMID 30156984, PMID 31538815, PMID 31776899, PMID 31853265, PMID 32877583, PMID 33892407, PMID 34347542, PMID 34376578, PMID 34543871, PMID 35292802, PMID 36822130, PMID 38617599, PMID 38763104, PMID 38986421, PMID 39362249, PMID 41838385, PMID 41914670, PMID 42686334
2014 (3), 2018 (2), 2019 (2), 2015 (1), 2016 (1), 2023 (1), U10CA180888 (1)